Cancer researchers link DICER1 gene mutation to rare childhood cancer

June 25, 2009

WASHINGTON, DC--Research published today in Science Express from the journal Science demonstrates the first definitive link between mutations in the gene DICER1 and cancer. By studying the patterns of DNA from 11 families with an unusual predisposition to the rare childhood lung cancer pleuropulmonary blastoma (PPB) investigators found that children with the cancer carried a mutation in one of their two DICER1 gene copies.

DICER1 makes an important protein that works to suppress other genes through intermediary molecules known as microRNAs. Scientists have learned that microRNAs can fine-tune the expression of many other genes, which is particularly important in normal human development. Recent research has also focused on DICER1 as having a potential role in cancer because the micro-RNA molecules it produces appear vastly different from normal when found in cancer cells; some suggest that the pattern of microRNAs in cancers resembles an embryonic stage.

"When we realized that DICER1 was in the segment of chromosome that was shared among children with PPB we were very excited," said D. Ashley Hill, MD, lead author and chief of Pathology at Children's National Medical Center.

"PPB is a tumor that appears to arise out of a localized area of abnormal lung development. The implications of a defect in a master controller gene for normal organ development would be significant."

Hill says not everyone who inherits a mutation develops PPB and children with PPB are typically normal in every other way. The team theorizes that something else must happen to the normal copy of DICER1 in lung cells for a tumor to develop. When the research team looked at PPB tumors to see if there is any DICER1 protein being made from the remaining normal copy of the gene, they were surprised by the results: "We expected to see that the tumor cells had no DICER1 protein giving us a nice explanation for why the tumor cells had gone haywire." But that wasn't the case.

They found that the benign cells that grew on the surface of the tumor had lost the DICER1 protein. "During lung development the cells that line the airways and the cells that make up the support structures have to communicate." Hill explained. "Loss of DICER1 in the airway lining cells could disrupt this communication, possibly setting the stage for abnormal growth."

Studying tumor cells for genetic mutations has led to many advances in the understanding of cancer. This discovery may represent a first step in understanding a new mechanism for how cancer begins. Conceivably, the mutated cells do not turn into tumors themselves. Instead, these cells influence surrounding cells to grow quickly, setting the stage for additional genetic mutations in cells that then become cancerous. Hill's team will now focus on demonstrating the sequence of events that result from loss of DICER1.

Only 50 or 60 cases of PPB are diagnosed worldwide each year. The cancer presents as cysts in early stages and progresses to solid lung tumors over time. If detected in the earliest stages, 90 percent of patients appear to be cured when treated with a surgical intervention and sometimes chemotherapy.
-end-
The research was conducted at Children's National Medical Center, the International Pleuropulmonary Blastoma Registry at Children's Hospitals and Clinics of Minnesota, and Washington University School of Medicine and other collaborating institutions.



About Children's National Medical Center


Children's National Medical Center, located in Washington, DC, is a proven leader in the development of innovative new treatments for childhood illness and injury. Children's has been serving the nation's children for more than 135 years. Children's National is proudly ranked among the best pediatric hospitals in America by US News & World Report and the Leapfrog Group. For more information, visit www.childrensnational.org. Children's Research Institute, the academic arm of Children's National Medical Center, encompasses the translational, clinical, and community research efforts of the institution. Learn more about our research programs at www.childrensnational.org/research.

Children's National Health System

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.